Skip to main navigation Skip to search Skip to main content

Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

  • Cathrine Axfors
  • , Andreas M. Schmitt
  • , Perrine Janiaud
  • , Janneke van’t Hooft
  • , Sherief Abd-Elsalam
  • , Ehab F. Abdo
  • , Benjamin S. Abella
  • , Javed Akram
  • , Ravi K. Amaravadi
  • , Derek C. Angus
  • , Yaseen M. Arabi
  • , Shehnoor Azhar
  • , Lindsey R. Baden
  • , Arthur W. Baker
  • , Leila Belkhir
  • , Thomas Benfield
  • , Marvin A. H. Berrevoets
  • , Cheng-Pin Chen
  • , Tsung-Chia Chen
  • , Shu-Hsing Cheng
  • Chien-Yu Cheng, Wei-Sheng Chung, Yehuda Z. Cohen, Lisa N. Cowan, Olav Dalgard, Fernando F. de Almeida e Val, Marcus V. G. de Lacerda, Gisely C. de Melo, Lennie Derde, Vincent Dubee, Anissa Elfakir, Anthony C. Gordon, Carmen M. Hernandez-Cardenas, Thomas Hills, Andy I. M. Hoepelman, Yi-Wen Huang, Bruno Igau, Ronghua Jin, Felipe Jurado-Camacho, Khalid S. Khan, Peter G. Kremsner, Benno Kreuels, Cheng-Yu Kuo, Thuy le, Yi-Chun Lin, Wu-Pu Lin, Tse-Hung Lin, Magnus Nakrem Lyngbakken, Colin McArthur, Bryan J. McVerry, Patricia Meza-Meneses, Wuelton M. Monteiro, Susan C. Morpeth, Ahmad Mourad, Mark J. Mulligan, Srinivas Murthy, Susanna Naggie, Shanti Narayanasamy, Alistair Nichol, Lewis A. Novack, Sean M. O’Brien, Nwora Lance Okeke, L. na Perez, Rogelio Perez-Padilla, Laurent Perrin, Arantxa Remigio-Luna, Norma E. Rivera-Martinez, Frank W. Rockhold, Sebastian Rodriguez-Llamazares, Robert Rolfe, Rossana Rosa, Helge Røsjø, Vanderson S. Sampaio, Todd B. Seto, Muhammad Shahzad, Shaimaa Soliman, Jason E. Stout, Ireri Thirion-Romero, Andrea B. Troxel, Ting-Yu Tseng, Nicholas A. Turner, Robert J. Ulrich, Stephen R. Walsh, Steve A. Webb, Jesper M. Weehuizen, Maria Velinova, Hon-Lai Wong, Rebekah Wrenn, Fernando G. Zampieri, Wu Zhong, David Moher, Steven N. Goodman, John P. A. Ioannidis, Lars G. Hemkens*
*Corresponding author for this work
  • Stanford University
  • Uppsala University
  • University of Basel
  • Amsterdam UMC - University of Amsterdam
  • Tanta University
  • Faculty of Medicine
  • University of Pennsylvania
  • University of Health Sciences Lahore
  • University of Pittsburgh
  • Department of Neurology, Stroke Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
  • King Saud bin Abdulaziz University for Health Sciences
  • Brigham and Women’s Hospital
  • Duke University
  • Université catholique de Louvain
  • University of Copenhagen
  • Department of Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
  • Tao-Yuan General Hospital
  • Taichung Hospital
  • Sanofi-Aventis
  • University of Oslo
  • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
  • Fundação Oswaldo Cruz
  • Universidade do Estado do Amazonas
  • University Medical Center Utrecht
  • Université d'Angers
  • Ividata Life Sciences, Levallois-Perret, France
  • Imperial College Healthcare NHS Trust
  • Instituto Nacional de Enfermedades Respiratorias
  • Medical Research Institute of New Zealand
  • Auckland City Hospital
  • Department of Internal Medicine, Chang Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan
  • Capital Medical University
  • University of Granada
  • University of Tübingen
  • Centre de Recherches Médicales de Lambaréné
  • German Center for Infection Research, Partner Site Tübingen, Tübingen, Germany
  • University of Hamburg
  • Bernhard Nocht Institute for Tropical Medicine
  • Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Pingtung, Taiwan
  • Taipei Hospital
  • Monash University
  • Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI) “Reference clinic for haemato-oncological diseases during pregnancy CREHER”, Estado de México, México
  • Middlemore Hospital
  • New York University
  • Faculty of Medicine, University of British Columbia School of Medicine, Vancouver, British Columbia, Canada
  • Department of Intensive Care, Alfred Health, Melbourne, VIC, Australia
  • University College Dublin
  • Harvard University
  • Excelya, Montpellier, France
  • Hospital Regional de Alta Especialidad de Oaxaca
  • UnityPoint Health
  • Fundação de Vigilância em Saúde do Amazonas, Manaus, AM, Brazil
  • University of Hawai'i at Mānoa
  • Queen's Medical Center Hawaii
  • Menoufia University
  • St John of God Health Care
  • PRA Health Science, Groningen, Netherlands
  • Keelung Hospital
  • Universidade de São Paulo
  • Brazilian Research in Intensive Care Network (BRICNet)
  • IDor Research Institute, São Paulo, Brazil
  • Beijing Institute of Pharmacology and Toxicology
  • University of Ottawa
  • Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin

Research output: Contribution to journalErratum/CorrigendumAcademic

12 Downloads (Pure)

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-021-22446-z, published online 15 April 2021 The original version of this article contained an error in Table 1, which misidentified the trial included in the meta-analysis registered as NCT04323527 as CloroCOVID19II instead of CloroCOVID19III. The NCT04323527 registration includes the trials CloroCOVID19I and CloroCOVID19III. CloroCOVID19I was not included in the meta-analysis. In addition, the original version of the Methods section inadvertently omitted details of which formulations of hydroxychloroquine or chloroquine the reported dosages refer to. The following information has been included in the legend for Table 1 and in the corrected methods section: “In all trials that used hydroxychloroquine, dosages refer to hydroxychloroquine sulfate. In trials that used chloroquine, the dosages for ARCHAIC, ChiCTR2000030054 and ChiCTR2000031204 refer to chloroquine phosphate, while those for CloroCOVID19II and CloroCOVID19III refer to chloroquine base. The American Journal of Tropical Medicine and Hygiene has issued a retraction note (1) for one of the trials (2) that had been included in the calculations of our meta-analysis. Exclusion of the data from this trial changes neither the results nor inferences of the meta-analysis. For hydroxychloroquine, the original odds ratio for mortality was 1.11 (95% CI: 1.02–1.20; I2 = 0%; 26 trials; 10,012 patients) and excluding the retracted trial the odds ratio for mortality would remain 1.11 (95% CI: 1.02–1.20, I2 = 0%; 25 trials; 9818 patients). Retraction Notice. The American Journal of Tropical Medicine and Hygiene 107, 728-728, https://doi.org/10.4269/ajtmh.1073ret (2022). Abd-Elsalam, S. et al. RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. Am J Trop Med Hyg 103, 1635-1639, https://doi.org/10.4269/ajtmh.20-0873 (2020). The errors in Table 1 and in the Methods section have been corrected in both the PDF and HTML versions of the Article.
Original languageEnglish
Article number1075
JournalNature communications
Volume15
Issue number1
DOIs
Publication statusPublished - 5 Feb 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials'. Together they form a unique fingerprint.

Cite this